Method to evaluate the dustiness of pharmaceutical powders

被引:41
|
作者
Boundy, Maryanne [1 ]
Leith, David
Polton, Thomas
机构
[1] Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA
[2] Pfizer Inc, New York, NY 10017 USA
来源
ANNALS OF OCCUPATIONAL HYGIENE | 2006年 / 50卷 / 05期
关键词
dustiness measurement; pharmaceuticals; toxic powders;
D O I
10.1093/annhyg/mel004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The trend among pharmaceutical companies to develop selective drugs of high potency has pushed the industry to consider the potential of each hazardous ingredient to become airborne. Dustiness issues are not unique to the pharmaceutical industry, but are relevant to any industry where powdered materials are mixed, transferred and handled. Interest in dustiness is also driven by concerns for worker health, the potential for plant explosions and the prevention of product loss. Unlike other industries, the pharmaceutical industry is limited by the milligram quantity of powdered material available for testing during product development. These needs have led to the development of a bench-top dustiness tester that requires only 10 mg of powder and fully contains the generated aerosol. The powder is dispersed within a 5.7 liter glass chamber that contains a respirable mass sampler and a closed-face sampler to quantify the respirable and total dust that are generated with a given energy input. The tester distinguished differences in dustiness levels of five different powders. Finer powders were dustier, and the respirable dust percentage was always less than that for total dust. Four testers have been built and evaluated using pharmaceutical grade lactose. Dustiness measurements determined using all four testers were comparable. The pharmaceutical industry uses surrogates such as lactose to represent active compounds in tests that estimate the dust concentration likely to occur in a new manufacturing operation. Differences between the dustiness of the active compound and its surrogate challenge the relevance of the surrogate tests to represent true exposures in the workplace. The tester can determine the dustiness of both the active compound and its surrogate, and the resultant ratio can help to interpret dust concentrations from surrogate tests. Further, dustiness information may allow the pharmaceutical researcher to select powder formulations that present low airborne concentrations in the workplace.
引用
收藏
页码:453 / 458
页数:6
相关论文
共 50 条
  • [41] LIQUID PENETRATION AS A METHOD OF ASSESSING THE WETTABILITY AND SURFACE-ENERGY OF PHARMACEUTICAL POWDERS
    BUCKTON, G
    NEWTON, JM
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1986, 38 (05) : 329 - 334
  • [42] EXPOSURE ASSESSMENT OF PHARMACEUTICAL POWDERS BASED ON AN ENVIRONMENTAL MONITORING METHOD: A PILOT STUDY
    Yildirim, Fatma Demircan
    Ekmekci, Ismail
    MEDYCYNA PRACY, 2020, 71 (06) : 649 - 663
  • [43] Analysis of the milling rate of pharmaceutical powders using the Distinct Element Method (DEM)
    Kwan, CC
    Mio, H
    Chen, YQ
    Ding, YL
    Saito, F
    Papadopoulos, DG
    Bentham, AC
    Ghadiri, M
    CHEMICAL ENGINEERING SCIENCE, 2005, 60 (05) : 1441 - 1448
  • [44] Dustiness behaviour of loose and compacted Bentonite and organoclay powders: What is the difference in exposure risk?
    Keld Alstrup Jensen
    Ismo Kalevi Koponen
    Per Axel Clausen
    Thomas Schneider
    Journal of Nanoparticle Research, 2009, 11 : 133 - 146
  • [45] An improved method to evaluate the quality of glass tubing as a raw material for pharmaceutical articles
    Guadagnino, Emanuel
    Zuccato, Daniele
    Gloder, Chiara
    Mason, Diego
    GLASS TECHNOLOGY-EUROPEAN JOURNAL OF GLASS SCIENCE AND TECHNOLOGY PART A, 2011, 52 (06): : 203 - 209
  • [46] Determining the dustiness of powders - comparison measurements with one of the reference test methods according to EN 15051
    Bach, S.
    Schmidt, E.
    GEFAHRSTOFFE REINHALTUNG DER LUFT, 2008, 68 (1-2): : 25 - 31
  • [47] INFLUENCE OF PARTICLE SIZE ON PHYSICOCHEMICAL PROPERTIES OF PHARMACEUTICAL POWDERS .4. ON PACKING OF PHARMACEUTICAL POWDERS (2)
    IKEKAWA, A
    KANENIWA, N
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1968, 16 (07) : 1174 - +
  • [48] Methods to Assess Mixing of Pharmaceutical Powders
    Crouter, Allison
    Briens, Lauren
    AAPS PHARMSCITECH, 2019, 20 (02)
  • [49] Agglomerate strength and dispersion of pharmaceutical powders
    Adi, Santoso
    Adi, Handoko
    Chan, Hak-Kim
    Finlay, Warren H.
    Tong, Zhenbo
    Yang, Runyu
    Yu, Aibing
    JOURNAL OF AEROSOL SCIENCE, 2011, 42 (04) : 285 - 294
  • [50] Flow of powders - Application to the pharmaceutical industry
    Pourcelot, Y
    Chulia, D
    ANALUSIS, 1996, 24 (01) : M33 - M35